Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).

Abstract

BACKGROUND:

Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpatients with COVID-19 (TICO). TICO is a multi-arm, multi-stage (MAMS) platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate anti-viral therapeutic agents for adults hospitalized with COVID-19. Four agents have so far entered the protocol, with rapid answers already provided for three of these. Other agents are expected to enter the protocol throughout 2021. This protocol contains a number of key design and implementation features that, along with challenges faced by the protocol team, are presented and discussed.

PROTOCOL DESIGN AND IMPLEMENTATION:

Three clinical trial networks, encompassing a global network of clinical sites, participated in the protocol development and implementation. TICO utilizes a MAMS design with an agile and robust approach to futility and safety evaluation at 300 patients enrolled, with subsequent expansion to full sample size and an expanded target population if the agent shows an acceptable safety profile and evidence of efficacy. Rapid recruitment to multiple agents is enabled through the sharing of placebo as well as the confining of agent-specific information to protocol appendices, and modular consent forms. In collaboration with the Food and Drug Administration, a thorough safety data collection and DSMB schedule was developed for the study of agents with limited in-human data.

CHALLENGES:

Challenges included ensuring drug supply and reliable recruitment allowing for changing infection rates across the global network of sites, the need to balance the collection of data and samples without overburdening clinical staff, and obtaining regulatory approvals across a global network of sites.

CONCLUSION:

Through a robust multi-network partnership, the TICO protocol has been successfully used across a global network of sites for rapid generation of efficacy data on multiple novel antiviral agents. The protocol design and implementation features used in this protocol, and the approaches to address challenges, will have broader applicability. Mechanisms to facilitate improved communication and harmonization among country-specific regulatory bodies are required.

• Authors: Daniel D Murray, Abdel G Babiker, Jason V Baker, Christina E Barkauskas, Samuel M Brown, Christina C Chang, Victoria J Davey, Annetine C Gelijns, Adit A Ginde, Birgit Grund, Elizabeth Higgs, Fleur Hudson, Virginia L Kan, H Clifford Lane, Thomas A Murray, Roger Paredes, Mahesh K B Parmar, Sarah Pett, Andrew N Phillips, Mark N Polizzotto, Cavan Reilly, Uriel Sandkovsky, Shweta Sharma, Marc Teitelbaum, B Taylor Thompson, Barnaby E Young, James D Neaton, Jens D Lundgren
• Journal: medRxiv : the preprint server for health sciences (medRxiv) (Apr 08 2021) United States
• PMID: 33215168 (Publication Type: Preprint)